==== 2025-09-05 ====
reading journal:
  * https://www.cnbc.com/video/2025/09/05/jpmorgan-big-gains-for-discretionary-goods-after-indias-gst-revamp.html - JPMorgan predicts big gains for discretionary goods after India’s GST revamp
    * Rajiv Batra, Head of Asia & Co-Head of Global Emerging Markets Equity Strategy at JPMorgan

  * https://www.barrons.com/articles/tech-energy-healthcare-stocks-markets-cf964dda - As Tech Stocks Rally, Risk Rises. Why Energy and Healthcare Could Be Options.
    * the Shearwater Platform, a joint venture of Shell and Exxon Mobil off the coast of Aberdeen, Scotland
    * This past week, tech accounted for a record 34.5% of the index’s total market capitalization of \$54 trillion. That’s up from 32% at the end of 2024 and 20% in 2018.
    * S&P Dow Jones Indices, which oversees the benchmark, categorizes Meta Platforms and Alphabet as communication services stocks, Amazon.com as a consumer discretionary stock and Tesla as (an artificial-intelligence, robotics, and autonomous-driving play)
    * the entire healthcare sector at \$4.7 trillion
    * energy has a \$1.5 trillion market cap
    * tech stocks trading at an average of 30 times forward earnings and 10 times sales
    * Healthcare, energy, and financials are valued at closer to 15 times earnings
    * Ten times sales used to be viewed as an outlandish valuation, but Nvidia now trades for 20 times 2025 sales, and Palantir for almost 100 times.
    * Alphabet is projecting \$85 billion of capex this year, up from \$52 billion in 2024, and Meta sees about \$70 billion in 2025, against \$39 billion in 2024
    * the Smead Value fund
    * the Energy Select Sector SPDR ETF
    * cheaply valued E&P companies like Diamondback Energy, ConocoPhillips, Occidental Petroleum (a Warren Buffett favorite), and APA
    * Exxon Mobil and Chevron, are safer plays and trade for about 15 times forward earnings and yield about 4%.
    * Their European counterparts BP and Shell are even cheaper
    * SLB - formerly Schlumberger trades for about 10 times earnings
    * industry leaders, Eli Lilly and UnitedHealth Group
    * Lilly is dominant in diet drugs with injectables Zepbound and Mounjaro and is seeking to solidify that position with a diet pill known as orforglipron, which uses the same GLP-1 formula as the injectable drugs and could be on the market in the second half of 2026.
    * Lilly CEO Dave Ricks
    * Elevance Health, formerly Anthem
    * Value investors like Dodge & Cox
    * Elevance CEO Gail Boudreax
